Inner Mongolia Furui Medical Hits Day High with 6.03% Surge

Inner Mongolia Furui Medical Science Co., Ltd. has experienced a notable increase of 6.03% on June 11, 2026, reaching an intraday high of CNY 43.80. This performance stands in contrast to the China Shanghai Composite, which saw a slight decline of 0.16% on the same day. Over the past year, Inner Mongolia Furui has delivered a robust return of 28.65%, significantly outperforming the Shanghai Composite's 17.19%. However, the stock has faced challenges in the short term, with a year-to-date decline of 39.28%. Financial metrics indicate a strong operational performance, with net sales for the first half of the year reported at CNY 854.49 million, reflecting a growth rate of 22.15%. Additionally, net profit surged by 88.28% to CNY 75.16 million. The company boasts a return on equity of 13.58% and a price-to-book ratio of 4.67, suggesting a premium valuation in the market. As a mid-cap player in the pharmaceuticals and biotechnology sector, Inner Mongolia Furui continues to navigate a dynamic market landscape while showcasing significant growth in key financial indicators.